CinCor Pharma, Inc.
CINCDelisted Feb 24, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868734
CinCor Pharma, Inc. was delisted on Feb 24, 2023; its insiders filed their last Form 4 on Feb 28, 2023; 102 institutions reported holding it in 13F filings for Q4 2022, worth $460.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by CinCor Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for CinCor Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schwab Andrew J. | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| Parmar Kush | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Opportunities I, L.P. | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Ventures VI, L.P. | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Opportunities I (GP), LLC | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Partners VI, LLC | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Opportunities II, L.P. | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| 5AM Opportunities II (GP), LLC | 10% Owner | 0Indirect | Feb 28, 2023 | 0 |
| Healy James | Director, 10% Owner | 0Indirect | Feb 27, 2023 | 0 |
| Sofinnova Management X, L.P. | 10% Owner | 0Indirect | Feb 27, 2023 | 0 |
| Sofinnova Venture Partners X, L.P. | 10% Owner | 0Indirect | Feb 27, 2023 | 0 |
| Katabi Maha | 10% Owner | 0Indirect | Feb 27, 2023 | 0 |
| Sofinnova Management X-A, L.L.C. | 10% Owner | 0Indirect | Feb 27, 2023 | 0 |
| Freeman Mason | Chief Medical Officer | 0Indirect | Feb 27, 2023 | 0 |
| Thero John F | Director | – | Feb 24, 2023 | 0 |
| Ignelzi Troy A. | Director | – | Feb 24, 2023 | 0 |
| Kalb Michael Wayne | EVP & Chief Financial Officer | 0 | Feb 24, 2023 | 0 |
| Lee June | Director | – | Feb 24, 2023 | 0 |
| Allison David D. | Director | – | Feb 24, 2023 | 0 |
| Pearce Catherine | Chief Operating Officer | 0Indirect | Feb 24, 2023 | 0 |
| de Garidel Marc | Chief Executive Officer | 0 | Feb 24, 2023 | 0 |
| Sofinnova Partners SAS | 10% Owner | 4,220,979Indirect | Aug 17, 2022 | 0 |
| Sofinnova Capital IX | 10% Owner | 4,220,979Indirect | Aug 17, 2022 | 0 |
| GAP Coinvestments CDA, L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| GAP (Bermuda) L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic Genpar (Bermuda), L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic (SPV) GP, LLC | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic (CIN), L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic, L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| Gap Coinvestments III, LLC | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| Gap Coinvestments IV, LLC | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic Genpar, L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic Partners (Bermuda) EU, L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic Partners 100, L.P. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| GAP Coinvestments V, LLC | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic Partners (Lux), SCSp | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic GenPar (Lux) SCSp | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| General Atlantic (Lux) S.a r.l. | 10% Owner | 4,209,470Indirect | Aug 15, 2022 | 0 |
| Coelho Mary Theresa | EVP CFO & Chief BD Officer | 100Indirect | Jan 13, 2022 | 0 |
| CinRx Pharma, LLC | 10% Owner | 3,630,103 | Jan 13, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)9:15 PM ET | Nov 28, 2022 | 91 daysLate | Healy James and 4 othersDirector, 10% Owner | SSale | −6.00K | $14.32 | −$85.9K | −100.0%0 after | |
| Feb 27, 2023 (view filing) | Jun 10, 2022 | 262 daysLate | Freeman MasonChief Medical Officer | SSale | −6 | $15.21 | −$91.26 | −0.2%2.49K after | |
| Aug 17, 2022 (view filing)8:01 PM ET | Aug 15 | 2 days | Schwab Andrew J. and 7 others10% Owner | PPurchase | +600.0K | $30.00 | +$18.0M | New position487.3K after | 2 lots |
| Aug 17, 2022 (view filing)4:19 PM ET | Aug 15 | 2 days | Sofinnova Partners SAS and 1 other10% Owner | PPurchase | +133.3K | $30.00 | +$4.00M | +3.3%4.22M after | |
| Aug 15, 2022 (view filing)3:46 PM ET | Aug 11 | 4 days | Sofinnova Management X, L.P. and 2 others10% Owner | PPurchase | +500.0K | $30.00 | +$15.0M | +9.0%6.07M after | |
| Aug 15, 2022 (view filing)2:22 PM ET | Aug 11 | 4 days | GAP Coinvestments CDA, L.P. and 4 others10% Owner | PPurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | +83.0K | $30.00 | +$2.49M | +2.0%4.21M after | Duplicate filing |
| Aug 15, 2022 (view filing)2:21 PM ET | Aug 11 | 4 days | General Atlantic, L.P. and 9 others10% Owner | PPurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | +83.0K | $30.00 | +$2.49M | +2.0%4.21M after | |
| Aug 15, 2022 (view filing) | Aug 11 | 4 days | Healy JamesDirector, 10% Owner | PPurchase | +506.0K | $30.00 | +$15.2M | New position6.00K after | 2 lots |
| Jan 13, 2022 (view filing)9:32 PM ET | Jan 11 | 2 days | GAP Coinvestments CDA, L.P. and 4 others10% Owner | PPurchase | +1.70M | $16.00 | +$27.2M | +70.1%4.13M after | Duplicate filing |
| Jan 13, 2022 (view filing)9:32 PM ET | Jan 11 | 2 days | General Atlantic, L.P. and 9 others10% Owner | PPurchase | +1.70M | $16.00 | +$27.2M | +70.1%4.13M after | |
| Jan 13, 2022 (view filing)4:45 PM ET | Jan 11 | 2 days | Schwab Andrew J. and 5 others10% Owner | PPurchase | +470.0K | $16.00 | +$7.52M | +1,785.5%496.3K after | 2 lots |
| Jan 13, 2022 (view filing)4:38 PM ET | Jan 11 | 2 days | Sofinnova Management X, L.P. and 2 others10% Owner | PPurchase | +325.0K | $16.00 | +$5.20M | +6.2%5.57M after | Duplicate filing |
| Jan 13, 2022 (view filing)4:36 PM ET | Jan 11 | 2 days | Sofinnova Partners SAS and 1 other10% Owner | PPurchase | +220.0K | $16.00 | +$3.52M | +5.7%4.09M after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Healy JamesDirector, 10% Owner | PPurchase | +325.0K | $16.00 | +$5.20M | +6.2%5.57M after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Pearce CatherineChief Operating Officer | PPurchase | +750 | $16.00 | +$12.0K | +0.6%130.9K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Pearce CatherineChief Operating Officer | PPurchase | +1.50K | $16.00 | +$24.0K | New position1.50K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Freeman MasonEVP Clinical Development | PPurchase | +2.50K | $16.00 | +$40.0K | New position2.50K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Freeman MasonEVP Clinical Development | PPurchase | +100 | $16.00 | +$1.60K | New position100 after | Duplicate filing |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | de Garidel MarcChief Executive Officer | PPurchase | +12.5K | $16.00 | +$200.0K | New position12.5K after | |
| Jan 13, 2022 (view filing) | Jan 11 | 2 days | Coelho Mary TheresaEVP CFO & Chief BD Officer | PPurchase | +100 | $16.00 | +$1.60K | New position100 after |